Source-grounded facts extracted from Stereotaxis, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Stereotaxis, Inc. shareholders approved Proposal to approve on an advisory basis, by non-binding vote, executive compensation at the 2026-05-14 meeting.
“Proposal to approve on an advisory basis, by non-binding vote, executive compensation: Number of Votes For: 52,143,334 Number of Votes Against: 985,434 Number of Votes Abstain: 474,095 Number of Broker Non-Votes: 25,581,057”
Stereotaxis, Inc. shareholders approved Proposal to ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for fiscal year 2026 at the 2026-05-14 meeting.
“Proposal to ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for fiscal year 2026: Number of Votes For: 79,036,638 Number of Votes Against: 112,633 Number of Votes Abstain: 34,649”
Stereotaxis, Inc. shareholders approved Election of three Class I directors to serve until the Company's 2029 Annual Meeting at the 2026-05-14 meeting.
“Election of Directors: Name of Nominee Votes For Votes Against Votes Abstain/Withheld Broker Non-Votes Mr. David Benfer 52,225,420 1,364,215 13,228 25,581,057 Dr. Arun Menawat 49,544,105 4,050,991 7,767 25,581,057 Dr. Myriam Curet 52,711,903 868,378 22,582 25,581,057”
Stereotaxis, Inc. entered into Share Sale Agreement with Robocath, the Sellers, and the Manager valued at $20.0 million (effective 2026-04-14).
“On April 14, 2026, Stereotaxis, Inc. (“Stereotaxis” or the “Company”) entered into a Share Sale Agreement with Robocath, a French société par actions simplifiée , (“Robocath”), the shareholders of Robocath party thereto (the “Sellers”) and an individual serving as manager (the “Manager”) to acquire (the “Acquisition”) shares and other securities collectively representing 100% of the share capital and voting power of Robocath (on a fully-diluted basis) (the “Robocath Securities”) from the Sellers.”
Stereotaxis, Inc. reported the fourth quarter and full year ended December 31, 2025 results: revenue $8.6 million, net income ($5.5) million.
“will increasingly reach development, regulatory and commercial milestones.” 2025 Fourth Quarter and Full Year Financial Results Revenue for the fourth quarter of 2025 totaled $8.6 million, a 36% increase compared to $6.3 million in the prior year fourth quarter. System revenue for the quarter was $3.3 million and recurring revenue was $5.3 million, compared to”
Nachum Shamir was elected as Director at Stereotaxis, Inc..
“On July 18, 2024, Nachum “Homi” Shamir was elected to the Board of Directors of Stereotaxis, Inc. (the “Company”).”
Stereotaxis, Inc. shareholders approved Approve an amendment to the 2022 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for issuance thereunder by 250,000 shares at the 2024-05-15 meeting.
“(4) Proposal to approve an amendment to the 2022 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for issuance thereunder by 250,000 shares: Number of Votes For: 45,897,897 Number of Votes Against: 962,071 Number of Votes Abstain: 348,698 Number of Broker Non-Votes: 22,506,714”
Stereotaxis, Inc. shareholders approved Approve an amendment to the Stereotaxis, Inc. 2022 Stock Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder by 4,000,000 shares at the 2024-05-15 meeting.
“(3) Proposal to approve an amendment to the Stereotaxis, Inc. 2022 Stock Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder by 4,000,000 shares : Number of Votes For: 43,498,362 Number of Votes Against: 3,355,275 Number of Votes Abstain: 355,029 Number of Broker Non-Votes: 22,506,714”
Stereotaxis, Inc. shareholders approved Ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for fiscal year 2024 at the 2024-05-15 meeting.
“(2) Proposal to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for fiscal year 2024: Number of Votes For: 69,449,549 Number of Votes Against: 231,067 Number of Votes Abstain: 34,764”
Stereotaxis, Inc. shareholders approved Election of one director as a Class II director at the 2024-05-15 meeting.
“Proposal 1, the election of one director, was determined by a plurality of votes cast. The Board’s nominee for director was elected to serve until the Company’s 2027 annual meeting, consistent with the proposal, or until his successor is elected and qualified, by the votes set forth in the table below.”
Stereotaxis, Inc. entered into Voting and Support Agreement with certain shareholders of Seller who collectively hold approximately 60% of the voting power of the Seller (the “APT Shareholders”).
“Contemporaneously with the execution of the Share Purchase Agreement, Stereotaxis and certain shareholders of Seller who collectively hold approximately 60% of the voting power of the Seller (the “APT Shareholders”) entered into a voting and support agreement (the “Voting and Support Agreement”).”
Stereotaxis, Inc. entered into Share Purchase Agreement with APT Holding Company, Inc. (effective 2024-05-11).
“On May 11, 2024, Stereotaxis, Inc. (“Stereotaxis” or the “Company”) entered into a Share Purchase Agreement with APT Holding Company, Inc., a Minnesota corporation (the “Seller”), to acquire (the “Acquisition”) all of the equity interests of Access Point Technologies EP, Inc., a Minnesota corporation (“APT”).”
Stereotaxis, Inc. reported First quarter ended March 31, 2024 results: revenue $6.9 million, net income ($4.5) million. Guidance reaffirmed.
“Revenue for the first quarter of 2024 totaled $6.9 million, growth of 5% from $6.5 million in the prior year first quarter. System revenue for the first quarter was $2.6 million and recurring revenue was $4.3 million, compared to $1.8 million and $4.7 million in the prior year first quarter, respectively. Gross margin for the first quarter of 2024 was 58% of revenue. Recurring revenue gross margin was 76% and system gross margin was 27%. Operating expenses in the first quarter of $8.7 million include $2.6 million in non-cash stock compensation expense. Excluding non-cash stock compensation expense, adjusted operating expenses in the quarter were $6.1 million, compared to $6.9 million for adjusted operating expenses in the prior year first quarter. Operating loss and net loss for the first quarter of 2024 were ($4.7) million and ($4.5) million, respectively, compared to ($5.6) million and ($5.3) million in the previous year.”
Stereotaxis, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.
“On March 4, 2024, Stereotaxis, Inc. (the “Company”) issued a press release (the “Earnings Press Release”) setting forth its financial results for the 2023 fourth quarter and full year.”
Stereotaxis, Inc. reported the third quarter ended September 30, 2023 results: revenue $7.8 million, net income ($5.4) million.
“Revenue for the third quarter of 2023 totaled $7.8 million, compared to $7.7 million in the prior year third quarter.”
Stereotaxis, Inc. reported second quarter ended June 30, 2023 results: revenue $7.9 million, net income ($5.0) million.
“its commercialization, and reach profitability without the need for additional financing.” 2023 Second Quarter Financial Results Revenue for the second quarter of 2023 totaled $7.9 million, a 28% year-over-year increase compared to $6.2 million in the prior year second quarter. System revenue for the quarter was $3.3 million and recurring revenue was $4.6 million,”
Stereotaxis, Inc. shareholders approved Recommend, by non-binding vote, the frequency of future advisory votes on executive compensation at the 2023-05-18 meeting.
“The recommendation for the frequency of future advisory votes on executive compensation was for three (3) years, by votes set forth in the table below.”
Stereotaxis, Inc. shareholders approved Approve, by non-binding vote, executive compensation at the 2023-05-18 meeting.
“Number of Votes For: 38,666,726 Number of Votes Against: 3,439,809 Number of Votes Abstain: 899,918 Number of Broker Non-Votes: 21,585,293”
Stereotaxis, Inc. shareholders approved Ratify the appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year 2023 at the 2023-05-18 meeting.
“Number of Votes For: 64,193,577 Number of Votes Against: 283,410 Number of Votes Abstain: 114,759”
Stereotaxis, Inc. shareholders approved Election of three Class I directors to serve until the 2026 annual meeting at the 2023-05-18 meeting.
“All of the Board’s nominees for director were elected to serve until the Company’s 2026 annual meeting consistent with the proposal, or until their respective successors are elected and qualified, by the votes set forth in the table below.”
Stereotaxis, Inc. reported the first quarter ended March 31, 2023 results: revenue $6.5 million, net income ($5.3) million. Guidance reaffirmed.
“on May 19-21 and sharing meaningful updates on our innovation strategy at the conference.” 2023 First Quarter Financial Results Revenue for the first quarter of 2023 totaled $6.5 million compared to $7.0 million in the prior year first quarter. Revenue in these quarters were equivalent excluding catheter royalties received in the prior year. System revenue for”
Stereotaxis, Inc. reported the full year 2022 results: revenue $28.1 million.
“Revenue for the full year 2022 totaled $28.1 million compared to $35.0 million in 2021.”
Stereotaxis, Inc. reported the fourth quarter of 2022 results: revenue $7.3 million, net income ($4.2) million.
“Revenue for the fourth quarter of 2022 totaled $7.3 million, compared to $8.2 million in the prior year fourth quarter.”
Stereotaxis, Inc. reported the third quarter ended September 30, 2022 results: revenue $7.7 million, net income ($4.9) million.
“Revenue for the third quarter of 2022 totaled $7.7 million, compared to $9.1 million in the prior year third quarter. Recurring revenue for the third quarter was $5.3 million and system revenue was $2.4 million. The decrease in revenue is primarily driven by reduced system revenue, as hospital construction delays continue to slow the conversion of order backlog into revenue. Gross margin for the third quarter of 2022 was 60% of revenue, with recurring revenue gross margin of 80% and system gross margin of 16%. Operating expenses in the quarter of $9.6 million include $2.7 million in non-cash stock compensation expense. Excluding stock compensation expense, adjusted operating expenses were $6.9 million compared to $6.8 million in the prior year third quarter and down from $7.2 million sequentially from the current year second quarter. Operating loss and net loss for the third quarter of 2022 were ($5.1) million and ($4.9) million, respectively, compared to ($4.6) million for both in the”
Myriam Curet was elected as Director at Stereotaxis, Inc..
“On July 22, 2021, Myriam Curet, M.D. was elected to the Board of Directors of Stereotaxis, Inc. (the “Company”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.